Loading asset research
Protalix BioTherapeutics Inc. (DE) Common Stock
PLXNYSE · USD · StocksQuote as of · Exchange session not verified$2.64
-3.30%
Today
PLX
Loading 1D prices…
Market cap
$212.7M
Volume
645.4K
52w high
$3.1952w low
$1.60Company profile
Protalix BioTherapeutics Inc. (DE) Common Stock
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
NYSE
Display currency
USD
Location
Hackensack, NJ, United States
Employees
226
Fiscal year end
1231
CIK
1006281
Session & valuation
Open$2.74
Previous close$2.73
Day high$2.75
Day low$2.62
30-day avg. volume799.1K
Outstanding shares80.6M
Diluted EPS-$0.08
Latest annual period
P/E (trailing)11.48
P/E (forward)4.26
Price / book3.17
Beta0.02
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ABOSAcumen Pharmaceuticals Inc. Common Stock | $211.2M | $0.00 | — | -$2.00 | +2.10% | Buy |
| IPHAInnate Pharma S.A. ADS | $208.9M | — | — | -$0.55 | -0.53% | Buy |
| CHRSCoherus Oncology Inc. Common Stock | $205.5M | $42.2M | +398.43% | $1.43 | +0.00% | Buy |
| SRZNSurrozen Inc. Common Stock | $223.3M | $3.5M | -6960.77% | -$32.37 | -2.31% | Buy |
| TARAProtara Therapeutics Inc. Common Stock | $225.7M | $0.00 | — | -$1.34 | +1.32% | Buy |